Clinical Trials /

Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.

NCT03427866

Description:

This research study is studying a drug called Ruxolitinib as a possible treatment for Myelofibrosis.

Related Conditions:
  • Primary Myelofibrosis
  • Secondary Myelofibrosis
Recruiting Status:

Recruiting

Phase:

Phase 2

Trial Eligibility

Document

Title

  • Brief Title: Ruxolitinib Pre-, During- and Post-HSCT for Patients With Primary or Secondary Myelofibrosis.
  • Official Title: A Phase II Study of Ruxolitinib Pre-, During- and Post-Hematopoietic Stem Cell Transplantation for Patients With Primary or Secondary Myelofibrosis.

Clinical Trial IDs

  • ORG STUDY ID: 17-569
  • NCT ID: NCT03427866

Conditions

  • Myelofibrosis

Interventions

DrugSynonymsArms
RuxolitinibJakafiRuxolitinib Eligible pre-HSCT

Purpose

This research study is studying a drug called Ruxolitinib as a possible treatment for Myelofibrosis.

Detailed Description

      This research study is a Phase II clinical trial. Phase II clinical trials test the safety
      and effectiveness of an investigational drug to learn whether the drug works in treating a
      specific disease. "Investigational" means that the drug is being studied.

      The FDA (the U.S. Food and Drug Administration) has approved Ruxolitinib as a treatment
      option for this disease.

      This study examines two different cohorts of participants:

        -  Cohort 1: Participants who are eligible for Ruxolitinib therapy before transplant, based
           on their platelet counts. These participants will receive their first dose of the study
           drug between 2 and 6 months before HCT.

        -  Cohort 2: Participants who are not eligible for Ruxolitinib therapy pre-treatment based
           on their platelet counts. These participants will receive their first dose of
           Ruxolitinib 1 week before the conditioning period.

      Ruxolitinib is a medication that blocks certain proteins called tyrosine kinases.
      Specifically, it blocks tyrosine kinases called JAK2. Many cancers have over active "cell
      signaling." What this means is that certain functions in the cancer cells never turn off and
      this makes them grow in an uncontrolled way. Ruxolitinib, shuts down the pathway that depends
      on the JAK2 tyrosine kinases. The JAK2 pathway is over active in the participant's disease,
      acute myeloid leukemia. The exact way ruxolitinib does this is not yet clear but it may have
      to do with its ability to block the JAK2 pathway since this pathway can also lead to
      inflammation in the body.

      Ruxolitinib has also been shown to lower the rates of Graft-Versus-Host-Disease (GVHD), a
      complication of transplant. GVHD is a disease that occurs when the immune cells in
      transplanted donor tissue from your HCT attack the participant's own tissues and organs.
      There are two types of GVHD: acute and chronic. Acute GVHD generally occurs within 1 week to
      3 months after your HCT and may affect your skin, intestines, and liver. Chronic GVHD begins
      later on and may affect the organs prone to acute GVHD complications, as well as the lungs,
      mucous membranes, or other organs.

      There is also evidence that ruxolitinib is associated with reduced instances of enlarged
      spleen size after HCT. Enlarged spleens play a role in the engraftment rate after HCT, which
      is the rate at which donated tissue and your own tissue begin reproducing and growing
      together.

      In this research study, the investigators are:

        -  assessing the efficacy (how well the study drug works) and tolerability of Ruxolitinib
           before, during, and after HCT.

        -  examining the rates of GVHD after HCT when ruxolitinib is administered.

        -  determining whether engraftment rates improve when ruxolitinib is given
    

Trial Arms

NameTypeDescriptionInterventions
Ruxolitinib Eligible pre-HSCTExperimentalRuxolitinib will be taken orally at a fixed dose twice every day Dosing will be continuous, with a new cycle scheduled to start every 28 days. There will be no break in dosing between cycles Ruxolitinib can be administered with or without food.
  • Ruxolitinib
Ruxolitinib Not Eligible pre-HSCTExperimentalRuxolitinib will be taken orally at a fixed dose twice every day after transplant Dosing will be continuous, with a new cycle scheduled to start every 28 days. There will be no break in dosing between cycles Ruxolitinib can be administered with or without food.
  • Ruxolitinib

Eligibility Criteria

        Inclusion Criteria:

          -  Participants must have pathologically confirmed primary myelofibrosis according to WHO
             criteria1 or secondary myelofibrosis as defined by the IWG-MRT criteria.19

               -  Intermediate-2/ high-risk disease as per Dynamic IPSS (DIPSS) criteria2 (Appendix
                  1) OR

               -  Intermediate-1 risk disease with one of the following additional unfavorable
                  features known to impact the survival adversely

               -  Red cell transfusion dependency2

               -  Unfavorable Karyotype2

               -  Platelet count ≤100 x 109/L

          -  Age 18-75

          -  Participants must be designated to undergo reduced intensity allogeneic peripheral
             blood (PB) or bone marrow (BM) hematopoietic stem cell transplantation. Consent will
             be obtained prior to admission for HCT.

          -  Participants who will undergo HCT from the following donor types are eligible:

          -  5/6 or 6/6 (HLA-A, B, DR) matched related donor

          -  7/8 or 8/8 (HLA-A, B, DR, C) matched unrelated donor. Matching in the unrelated
             setting must be at the allele level

          -  ECOG performance status ≤2 (Karnofsky ≥60%, see Appendix A)

          -  Life expectancy of greater than 3 months

          -  Able to give informed consent

          -  Off all MF-directed therapy at the time of enrollment, with the exception of
             ruxolitinib

          -  Additional Criteria for Cohort 1 Only:

          -  Patients are canddates for enrollment in cohort 1 if they have an indication for
             ruxolitinib based on splenomegaly or symptoms and are either on ruxolitinib already or
             going to start therapy with ruxolitinib.

          -  Patients that are on ruxolitinib may enroll in study as long as they are willing to
             remain on ruxolitinib during the study and have not lost response to ruxolitinib
             defined as an increase in >5 cm in spleen size from nadir. There is no minimum or
             maximum time requirement for time on ruxolitinib.

          -  Participants must have splenomegaly (defined by ultrasound or CT scan of the abdomen)
             or symptoms (demonstrated by the presence of 1 symptom score >5 or 2 symptom scores
             >3) related to myelofibrosis as measured by the myeloproliferative neoplasm symptom
             assessment form MPN-SAF (see Appendix F) and platelets >25/μL and hemoglobin >7/dL

          -  Additional Criteria Cohort 2 Only:

          -  Participants are ineligible for ruxolitinib - do not have splenomegaly or symptoms of
             myelofibrosis as defined by the MPN-SAF.

        Or

          -  Participants failed ruxolitinib as defined by loss of response to therapy and

          -  No allergy to ruxolitinib in the past

        Exclusion Criteria:

          -  Hypersensitivity to any JAK inhibitor

          -  Prior allogeneic transplant for any hematopoietic disorder

          -  Had accelerated phase or leukemic transformation (≥10% blasts in PB or BM any time
             prior to HCT)

          -  Active uncontrolled infection

          -  History of another malignancy within 5-years of date of except h/o basal cell or
             squamous cell carcinoma of skin or Polycythemia Vera or Essential Thrombocythemia

          -  Patients without normal organ function defined as follows:

               -  AST (SGOT), ALT (SGPT) and Alkaline Phosphatase ≥ 3 × institutional Upper Limit
                  of Normal (ULN)

               -  Direct bilirubin >2.0 mg/dL

               -  Adequate renal function as defined by calculated creatinine clearance≤60 mL/min
                  (Cockcroft-Gault formula)

          -  Have a chronic or active infection that requires systemic antibiotics, antifungal or
             antiviral treatment

          -  Have current or a history of congestive heart failure New York Heart Association
             (NYHA) class 3 or 4, or any history of documented diastolic or systolic dysfunction
             (LVEF < 40%, as measured by MUGA scan or echocardiogram)

          -  Pregnancy at the time of enrollment

          -  Unable to give informed consent

          -  Have an uncontrolled intercurrent illness including, but not limited to, unstable
             angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that
             would limit compliance with study requirements.

          -  Subjects who require therapy with a strong CYP3A4 inhibitor prior to enrollment to
             this study

          -  Not able to take oral medication
      
Maximum Eligible Age:75 Years
Minimum Eligible Age:18 Years
Eligible Gender:All
Healthy Volunteers:No

Primary Outcome Measures

Measure:GVHD free and relapse free survival at 1 year
Time Frame:1 year
Safety Issue:
Description:The number of participants surviving after one year that have not experienced graft-versus host disease (GVHD) or relapse (GRFS rate)

Secondary Outcome Measures

Measure:Progression Free Survival
Time Frame:1 and 2 years
Safety Issue:
Description:Kaplan-Meier estimates of progression free survival (PFS) will be calculated, with patients without an event being censored at 1 and 2 years
Measure:Overall Survival
Time Frame:1 and 2 years
Safety Issue:
Description:Overal survival is measured as the time from the hematopoietic stem cell transplantation (HSCT) until death. Participants without an event will be censored at the date of last contact.
Measure:Cumulative incidence of aGVHD
Time Frame:6 months
Safety Issue:
Description:Cumulative incidence of grades II-IV and II-IV acute GVHD at 6 months after HSCT
Measure:Cumulative incidence of cGVHD
Time Frame:1 and 2 years
Safety Issue:
Description:Cumulative incidence of moderate to severe chronic GVHD at 1 year and 2 years after HSCT
Measure:Rate of Engraftment
Time Frame:2 years
Safety Issue:
Description:Engraftment defined as ANC >500/ugx3 consecutive measurements and platelets of >20x10e9/L for three consecutive days.
Measure:Median time on ruxolitinib after HSCT as a measure of feasibility
Time Frame:2 years
Safety Issue:
Description:The amount of time patients remain on ruxolitinib from transplant until discontinuation.
Measure:Toxicity rate
Time Frame:2 years
Safety Issue:
Description:Cumulative incidence of treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE 4). Early deaths from all other causes are considered a competing risk.

Details

Phase:Phase 2
Primary Purpose:Interventional
Overall Status:Not yet recruiting
Lead Sponsor:Massachusetts General Hospital

Trial Keywords

  • Myelofibrosis

Last Updated

April 12, 2018